1. Herceptin Hylecta is an injection for the treatment of human epidermal growth factor receptor 2-positive-overexpressing breast cancer. The previous version was given as an infusion into the vein, but this new formulation can be injected subcutaneously.
2. Adhansia XR is an extended release capsule for the treatment of ADHD in patients ages 6 years or older.
3. AstraZeneca received expanded use approvals for Farxiga and Xigduo. They are now approved for treating patients with Type 2 diabetes.
4. Lotemax SM is a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery.
More articles on supply chain:
Supplies of bladder cancer drug are dwindling
Washington faces critically low blood supply
Supply chain savings tip of the week: Manage your total transportation spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
